

Teva-sponsored satellite symposium at the
11th Congress of the European Academy of Neurology

Setting higher standards for migraine prophylaxis

Saturday 21 June | 14:15–15:15 EEST

Room Amsterdam, Messukeskus, Helsinki

Or view live and on-demand through the EAN virtual platform



teva

Setting higher standards for migraine prophylaxis

Welcome

Dear colleagues,

It is with great pleasure that I invite you to join us for the Teva-sponsored satellite symposium, taking place during the 11th Congress of the European Academy of Neurology.

Over the past 6 years in EU practice, emerging data have continuously informed and transformed our understanding of CGRP pathway mAbs and their role in migraine prevention. Equipped with these novel findings, our expert panel will consider how we can optimise the use of CGRP pathway mAbs to improve patient outcomes.

During this year's symposium, Giorgio Lambru, Gregor Brössner, and I will uncover new insights and discuss the evolving landscape of migraine prevention, drawing on 6 years of experience with CGRP pathway mAbs in Europe. We will discuss current preventive treatment options and the factors that influence treatment selection. Mapping out the clinical decisions that physicians make, we will explore the ways in which we can best optimise the use of monoclonal antibodies in clinical practice. Finally, we will review emerging data to inform the treatment of migraine in understudied patient populations.

I hope you will join us for what I anticipate will be an impactful and informative symposium.

Cristina Tassorelli (Chair), MD, PhD

**Neurological Institute C Mondino Foundation
Department of Brain and Behavioral Sciences,
University of Pavia
Pavia, Italy**

To register for the EAN congress, please visit <https://www.ean.org/congress2025/register/registration>. Whether you are joining us live or virtually, the symposium will include the opportunity to ask the faculty questions at the end of the presentations.

Programme



Welcome and introduction
6 years on in EU: From past assumptions to new insights
**Cristina Tassorelli (Chair),
Italy**



How can we optimise
CGRP pathway mAbs use for
better patients' outcomes?
**Gregor Brössner,
Austria**



Targeting the CGRP
ligand or receptor:
Does mechanism of action
have an impact?
**Giorgio Lambru,
UK**



Exploring new insights
to shape the future and
advance further
Closing remarks and Q&A
All faculty